middle.news
Dimerix Secures $107M Japan Deal as FDA Endorses Key Trial Endpoint
4:34am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Dimerix Secures $107M Japan Deal as FDA Endorses Key Trial Endpoint
4:34am on Monday 2nd of June, 2025 AEST
Key Points
FDA confirms proteinuria as acceptable primary endpoint for US marketing approval
Development and license agreement signed with Fuso Pharmaceutical for Japan
Up to AU$107 million in upfront, milestone payments, and royalties from Japan deal
Three licensing deals collectively valued at approximately AU$458 million plus royalties
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE